港股异动 | 百奥赛图-B(02315)逆市再涨超10% 已完成AI驱动抗体药物研发平台DeepSeek本地化部署

智通财经03-07

智通财经APP获悉，百奥赛图-B(02315)逆市再涨超10%，截至发稿，涨10.07%，报12.02港元，成交额12.52万港元。消息面上，百奥赛图-B公布，公司近期已完成人工智能(AI)驱动抗体药物研发平台深度求索(以下简称“DeepSeek”)的本地化部署，并实现其与公司核心业务“千鼠万抗”计划的全面协同。此次技术整合标志着抗体药物早期研发领域迈向智能化和数据化的新阶段，未来将为全球药企提供...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2517149110?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-03-07 09:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2517149110","market":"sh","top_or_hot":-1,"title":"港股异动 | 百奥赛图-B(02315)逆市再涨超10% 已完成AI驱动抗体药物研发平台DeepSeek本地化部署","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，百奥赛图-B(02315)逆市再涨超10%，截至发稿，涨10.07%，报12.02港元，成交额12.52万港元。消息面上，百奥赛图-B公布，公司近期已完成人工智能(AI)驱动抗体药物研发平台深度求索(以下简称“DeepSeek”)的本地化部署，并实现其与公司核心业务“千鼠万抗”计划的全面协同。此次技术整合标志着抗体药物早期研发领域迈向智能化和数据化的新阶段，未来将为全球药企提供...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1258894.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 百奥赛图-B(02315)逆市再涨超10% 已完成AI驱动抗体药物研发平台DeepSeek本地化部署</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 百奥赛图-B(02315)逆市再涨超10% 已完成AI驱动抗体药物研发平台DeepSeek本地化部署\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-07 09:52 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1258894.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，百奥赛图-B(02315)逆市再涨超10%，截至发稿，涨10.07%，报12.02港元，成交额12.52万港元。消息面上，百奥赛图-B公布，公司近期已完成人工智能(AI)驱动抗体药物研发平台深度求索(以下简称“DeepSeek”)的本地化部署，并实现其与公司核心业务“千鼠万抗”计划的全面协同。此次技术整合标志着抗体药物早期研发领域迈向智能化和数据化的新阶段，未来将为全球药企提供...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1258894.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02315","symbol_name":"百奥赛图-B","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1258894.html","article_id":"2517149110","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2517149110","pubTimestamp":1741312322,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，百奥赛图-B逆市再涨超10%，截至发稿，涨10.07%，报12.02港元，成交额12.52万港元。消息面上，百奥赛图-B公布，公司近期已完成人工智能驱动抗体药物研发平台深度求索的本地化部署，并实现其与公司核心业务“千鼠万抗”计划的全面协同。据介绍，百奥赛图通过“千鼠万抗”抗体分子库和DeepSeek平台的结合，可为全球药企提供全新的单抗、双抗和多抗分子骨架。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"02315":"百奥赛图-B"},"translate_title":"Hong Kong stocks changed Biocyto-B (02315) bucked the market trend and rose by more than 10%. It has completed the localization deployment of AI-driven antibody drug research and development platform DeepSeek","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02315":1},"content_text":"智通财经APP获悉，百奥赛图-B(02315)逆市再涨超10%，截至发稿，涨10.07%，报12.02港元，成交额12.52万港元。消息面上，百奥赛图-B公布，公司近期已完成人工智能(AI)驱动抗体药物研发平台深度求索(以下简称“DeepSeek”)的本地化部署，并实现其与公司核心业务“千鼠万抗”计划的全面协同。此次技术整合标志着抗体药物早期研发领域迈向智能化和数据化的新阶段，未来将为全球药企提供更精准及更具突破性的抗体药物研发方案，大大加速药物研发进程。据介绍，百奥赛图通过“千鼠万抗”抗体分子库和DeepSeek平台的结合，可为全球药企提供全新的单抗、双抗和多抗分子骨架。这些分子骨架具有高亲和力、低免疫原性和优异的成药性。借助DeepSeek平台，全球药企可以从“千鼠万抗”真实存在的千万级别抗体分子库中，快速筛选出具有极高成药潜力的目标抗体分子。DeepSeek 还可以通过模拟分子相互作用，借助“千鼠万抗”庞大抗体分子库筛选获得分子骨架，快速设计出具有特定功能的多特异性抗体，如双抗和多抗等，快速开发出针对各种疾病的创新抗体药物，大大加速药物研发进程，满足未被满足的临床需求。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,movement","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.4","shortVersion":"4.33.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2517149110"}